Overall, in subjects with T2DM, the significant reduction in the incretin effect has been attributed primarily to decreased circulating levels of GLP-1, which may be secondary to either increased degradation by DPP-IV or its decreased secretion by the gut [36]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.